Hanson Pharmaceuticals announced that from January 1, 2026 to June 30, 2026, net profit attributable to shareholders of listed companies is expected to be 103 million yuan to 116 million yuan, an increase of 50.28%-69.25% from 685.384 million yuan in the same period last year; net profit after deducting non-recurring profit and loss is 97.3 million yuan to 110 million yuan, an increase of 50.23%-69.83% from 64.7695 million yuan in the same period last year. This increase in performance is mainly due to an increase of more than 60 million yuan in investment income from joint ventures calculated under the equity method compared to the same period last year, an increase of 140%-150%.

Hanson Pharmaceuticals announced that from January 1, 2026 to June 30, 2026, net profit attributable to shareholders of listed companies is expected to be 103 million yuan to 116 million yuan, an increase of 50.28%-69.25% from 685.384 million yuan in the same period last year; net profit after deducting non-recurring profit and loss is 97.3 million yuan to 110 million yuan, an increase of 50.23%-69.83% from 64.7695 million yuan in the same period last year. This increase in performance is mainly due to an increase of more than 60 million yuan in investment income from joint ventures calculated under the equity method compared to the same period last year, an increase of 140%-150%.